RAPAMUNE 1 MG
SIROLIMUS : 1 MG · DIN 02247111 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is RAPAMUNE?
RAPAMUNE 1 MG contains SIROLIMUS : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02247111, held by PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 28-Feb-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RAPAMUNE used for?
Rapamune (sirolimus oral solution and tablets) is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal transplants: In patients at low to moderate immunological risk, it is recommended that Rapamune be used initially in a regimen with cyclosporine and corticosteroids. In patients at high immunologic risk, it is recommended that Rapamune be used in combination with cyclosporine and corticosteroids for the first year following transplantation.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02247111 |
|---|---|
| Brand name | RAPAMUNE |
| Generic / active ingredient | SIROLIMUS : 1 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 1 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L04AH01 SIROLIMUS |
| AHFS class | 90:28.24.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 28-Feb-2012 |
| Original market date | 2003-03-25 00:00:00 |
How is it administered?
Once daily, consistently with or without food. Take 4 hours after cyclosporine. Low/moderate risk: 6mg load, 2mg/day maintenance. High risk: 15mg load, 5mg/day maintenance.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
Oral Solution: Amber glass bottles of 60 mL. Tablet: Bottles of 100 tablets, Unit dose cartons of 100 tablets (10 blister cards of 10 tablets each).
Contraindications
Hypersensitivity to sirolimus, its derivatives, or any ingredient in the formulation.
Warnings and precautions
Increased susceptibility to infection/lymphoma. Not recommended for liver/lung transplants. Risk of angioedema, hyperlipidemia, and skin cancer (limit UV exposure).
What can be used instead?
Other Canadian products sharing ATC code L04AH01 SIROLIMUS. 2 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| RAPAMUNE | 1 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02243237 |
| GD-SIROLIMUS | 1 MG | SOLUTION | GENMED A DIVISION OF PFIZER CANADA ULC | APPROVED | DIN 02373386 |
| GD-SIROLIMUS | 1 MG | TABLET | GENMED A DIVISION OF PFIZER CANADA ULC | APPROVED | DIN 02373394 |
| GD-SIROLIMUS | 2 MG | TABLET | GENMED A DIVISION OF PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02373408 |
| GD-SIROLIMUS | 5 MG | TABLET | GENMED A DIVISION OF PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02373416 |
| RAPAMUNE | 2 MG | TABLET | PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02270617 |
| RAPAMUNE | 5 MG | TABLET | PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02270684 |
Who else supplies SIROLIMUS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SIROLIMUS appears in 83 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.